Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Andrew McConaghie

Senior Writer

Andrew is a London-based journalist who has been writing about pharma, biotech and healthcare for over 20 years.

He writes on a range of topics, including biopharma R&D and commercial issues, digital healthcare and issues affecting patients and global healthcare systems, especially the UK’s NHS.

Latest From Andrew McConaghie

AstraZeneca Sees Off Shareholder Revolt Over CEO’s Potential $25m Pay

A few years ago Pascal Soriot claimed to be the sector’s worst paid CEO, but share price-linked bonuses have bumped up his remuneration, and shareholders have now approved a new plan.

Companies Commercial

After Another Covid Vaccine Delay, Novavax’s Opportunity Is Shrinking

Novavax’s timelines are slipping once again, giving frontrunners Pfizer and Moderna the chance to consolidate their dominance in the market.

Commercial Companies

As COVID-19 Vaccine Sales Surge, BioNTech Pledges 40% Will Go To Poorer Nations

Angela Merkel consulted company’s CEO before opposing IP waiver, backing the future of Germany’s new ‘big biotech’ company.

Companies Commercial

At Last, AZ’s Imfinzi/Tremelimumab Cancer Combo Shows Survival Benefit

After five years of failure in NSCLC trials, AstraZeneca’s immunotherapy combo shows survival benefits in POSEIDON.

Commercial Companies

After World-Leading Vaccine Roll-Out, UK Eyes Booster Phase But Faces Pressure To Help Globe

The UK’s purchase of 60 million extra Pfizer/BioNTech COVID vaccine doses, plus bets on Novavax and Valneva and others gives it a buffer against new variants – so when will it pledge to donate to more needy nations?

Coronavirus COVID-19 Vaccines

IP Waiver Proposal Won’t Hold Back Moderna’s Rise

While White House support for an intellectual property waiver has been cheered by access campaigners, Moderna said it won’t help solve the pandemic’s big vaccine production challenges any time soon.

Commercial Companies
See All